Compass Pathways stock holds Buy rating on positive depression trial

Compass Pathways (CMPS) reported successful Phase 3 COMP005 trial results for its COMP360 psilocybin treatment for treatment-resistant depression (TRD), marking the first successful late-stage trial for a psychedelic therapy. A single 25mg dose demonstrated a statistically significant and clinically meaningful reduction in depressive symptoms at six weeks with no new safety concerns, positioning COMP360 as a potential first-in-class therapy for the projected $3.1 billion TRD market. H.C. Wainwright maintained its Buy rating and $45 price target, with further COMP005 data and the COMP006 trial readout in H2 2026 as key upcoming catalysts.

Analysis

Compass Pathways has achieved a significant clinical milestone with its COMP360 psilocybin therapy, marking the first successful late-stage trial for any psychedelic treatment. The Phase 3 COMP005 trial met its primary endpoint, demonstrating a "highly statistically significant and clinically meaningful reduction in depressive symptoms" with a single 25 mg dose at six weeks. This positive outcome, combined with a clean safety profile showing no new concerns, substantially de-risks the asset's path to potential approval. The therapy is positioned as a potential first-in-class treatment for the treatment-resistant depression (TRD) market, which is projected to reach $3.1 billion by 2025. The data provides strong validation for H.C. Wainwright's maintained Buy rating and $45.00 price target. Future valuation will be heavily influenced by upcoming catalysts, including more detailed data from the COMP005 trial and the 26-week results from the parallel COMP006 trial expected in the second half of 2026.

Key Decisions for Investors

• The successful Phase 3 data solidifies Compass Pathways' lead in the psychedelic medicine space, suggesting investors with an appetite for biotech risk could view this as a pivotal de-risking event.
• Investors should consider H.C. Wainwright's $45.00 price target as a key valuation benchmark, weighing the current share price against the potential upside now supported by positive late-stage clinical evidence.
• Monitor for key upcoming catalysts, namely the full data readout from the COMP005 trial and the longer-term results from the COMP006 trial in H2 2026, as these will be critical for regulatory submission and commercial viability.
• Given the timeline for the next major data release is over two years away, this opportunity is best suited for long-term investors who can tolerate the inherent clinical and regulatory risks of a pre-commercial biotech company.